Business Context and Reporting Period
Company: SANUWAVE Health, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2024
Business Overview: SANUWAVE focuses on commercializing patented noninvasive medical systems (UltraMIST and PACE) for tissue repair and regeneration. The company is classified as a smaller reporting company and a shell company is not applicable. As of August 8, 2024, there were approximately 1.18 billion shares of common stock outstanding.
Key Financial Metrics
| Metric | Three Months Ended June 30, 2024 | Six Months Ended June 30, 2024 | Balance Sheet (June 30, 2024) |
|---|---|---|---|
| Revenue | $7.16 million | $12.95 million | - |
| Net Income (Loss) | $6.56 million | $2.03 million | - |
| Operating Income (Loss) | $1.99 million | $0.94 million | - |
| Gross Margin | 73% | 73% | - |
| Cash and Cash Equivalents | - | - | $2.46 million |
| Total Assets | - | - | $21.01 million |
| Total Liabilities | - | - | $60.62 million |
| Stockholders' Deficit | - | - | ($39.61 million) |
| Senior Secured Debt (In Default) | - | - | $23.42 million |
Note: All figures in millions unless otherwise noted. The company reported a net income for the quarter and six-month period, a significant turnaround from net losses in the prior year periods.
Material Changes vs. Prior Period
- Revenue Growth: Revenue increased 53% year-over-year for both the three and six-month periods, driven by increased sales of the UltraMIST system and higher average selling prices for consumables.
- Profitability Turnaround: The company shifted from a net loss of $7.26 million (Q2 2023) to a net income of $6.56 million (Q2 2024). This was primarily due to a $5.31 million gain on the extinguishment of debt and a $3.72 million favorable change in the fair value of derivative liabilities.
- Debt Restructuring: A significant portion of the net income is attributable to a settlement of an acquisition dispute with Celularity, which resulted in the removal of $4.0 million in convertible notes and other liabilities, recognizing a gain on extinguishment of debt.
- Merger Termination: The company terminated its Merger Agreement with SEP Acquisition Corp. in June 2024, expensing $0.5 million in deferred offering costs.
- License Income: The company recognized $2.5 million in other income from a one-time payment related to an exclusive license and option agreement for intravascular shockwave patents.
Guidance, Outlook, Risks, and Unusual Items
Going Concern Warning
Management has raised substantial doubt about the company's ability to continue as a going concern for at least twelve months. This is due to recurring losses, events of default on notes payable, and a dependency on future equity or debt financing to fund operations.
Debt and Default Status
The company is in default on its Senior Secured Debt ($23.42 million carrying value) due to failure to meet minimum liquidity provisions. Interest is accruing at a default rate. A Sixth Amendment to the debt agreement was entered into in July 2024, providing forbearance until December 31, 2024, but adding a $0.7 million consent fee to the principal.
Unusual Items
- Gain on Extinguishment of Debt: $5.31 million recognized in Q2 2024 due to the settlement of the Celularity dispute.
- Change in Fair Value of Derivatives: A $3.72 million gain in Q2 2024 (vs. a $3.82 million loss in Q2 2023) related to warrant liabilities and embedded conversion options.
- License Fee: $2.5 million one-time income from a patent license agreement.
Internal Controls
Management concluded that disclosure controls and procedures were not effective as of June 30, 2024, citing three material weaknesses related to the lack of expertise in complex financial instruments, insufficient internal resources for GAAP application, and inadequate IT and accounting process controls.
Subsequent Events
On August 7, 2024, stockholders approved a reverse stock split (ratio between 1-for-300 and 1-for-500) and a new Equity Incentive Plan.
Investor Verification Checklist
- Debt Default Status: Verify the terms of the forbearance agreement on the Senior Secured Debt and the likelihood of further defaults or acceleration of payments.
- Going Concern Liquidity: Assess the company's ability to raise additional capital given the $39.6 million stockholders' deficit and $60.6 million in total liabilities.
- Non-Recurring Income: Confirm that the $6.6 million net income for Q2 2024 is not sustainable without the one-time debt extinguishment gain ($5.3M) and license fee ($2.5M).
- Internal Control Remediation: Monitor the progress of the remediation plan for the three identified material weaknesses in internal controls over financial reporting.
- Reverse Stock Split: Review the final ratio of the approved reverse stock split and its impact on share count and liquidity.